CRISPR screening reveals targets to reprogram long-lived effector CD8+ T cells for cancer therapy. [ATAC-Seq]
Ontology highlight
ABSTRACT: CD8+ T cells can be reprogrammed for better persistence and robust effector function in TME. By performing an in vivo pooled CRISPR-Cas9 mutagenesis screening of metabolism-associated factors, we identify Regnase-1 as a major negative regulator of antitumor responses, whose deficiency results in drastically increased CD8+ T cell accumulation in tumors
ORGANISM(S): Mus musculus
PROVIDER: GSE126070 | GEO | 2019/12/11
REPOSITORIES: GEO
ACCESS DATA